Highest Dose of Zepbound Currently Available
Zepbound (tirzepatide), approved by the FDA for chronic weight management in adults with obesity or overweight with weight-related conditions, has a highest available dose of 15 mg administered subcutaneously once weekly.[1]
How Doses Ramp Up
Treatment starts at 2.5 mg weekly for 4 weeks, then increases gradually every 4 weeks (5 mg, 7.5 mg, 10 mg, 12.5 mg) to reach 15 mg if tolerated and needed for response. This titration minimizes gastrointestinal side effects.[1][2]
Is 15 mg Suitable for Everyone?
Not all patients reach 15 mg; dose is individualized based on tolerance and weight loss goals. Clinical trials showed greater weight reduction at higher doses, with 15 mg patients losing up to 21% body weight over 72 weeks versus 15% at 10 mg.[2][3]
What If 15 mg Isn't Enough?
No higher FDA-approved dose exists. Off-label use beyond 15 mg lacks safety data and isn't recommended. Compounded tirzepatide versions sometimes claim higher strengths, but these are unregulated and carry risks like contamination.[1][4]
Pen Sizes and Availability
Zepbound comes in single-dose pens or vials: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL. The 15 mg pens deliver the full highest dose.[1]
Patent Protection on Doses and Formulation
Eli Lilly holds patents on tirzepatide through 2036, covering the molecule and dosing regimens, including the 15 mg strength. No generics or biosimilars are approved yet.[5]
[1]: Zepbound Prescribing Information (FDA/Lilly)
[2]: SURMOUNT-1 Trial (NEJM)
[3]: Zepbound FDA Approval Summary
[4]: FDA Warnings on Compounded Semaglutide/Tirzepatide
[5]: DrugPatentWatch: Tirzepatide Patents